Ipca Laboratories is trading higher by 2.2% at Rs 715, extending its yesterday’s 8.2% rally, after the drug maker said US health regulator has found its manufacturing facility in SEZ Indore acceptable after an inspection.
The stock opened at Rs 702 and hit a record high of Rs 730 on BSE. A combined around 50,000 shares change hands on the counter so far on BSE and NSE.
Management had earlier guided that once the approval is received, the facility would cater to the US generic market and potentially post sales of US$100mn in the next 2-3 years.
“Management expects the revenue from Indore SEZ to start from 4QFY2014. For FY2014 and FY2015, we have build in revenues of Rs 51crore and Rs 200 crore revenues from this facility, and hence upgrade our sales forecast by 1.5% and 6.7% respectively,” says analyst at Angel Broking in a note.
The stock opened at Rs 702 and hit a record high of Rs 730 on BSE. A combined around 50,000 shares change hands on the counter so far on BSE and NSE.
Management had earlier guided that once the approval is received, the facility would cater to the US generic market and potentially post sales of US$100mn in the next 2-3 years.
“Management expects the revenue from Indore SEZ to start from 4QFY2014. For FY2014 and FY2015, we have build in revenues of Rs 51crore and Rs 200 crore revenues from this facility, and hence upgrade our sales forecast by 1.5% and 6.7% respectively,” says analyst at Angel Broking in a note.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%